Bulletin
Investor Alert

New York Markets Close in:

Deciphera Pharmaceuticals Inc.

NAS: DCPH

GO
/marketstate/country/us

Market open

 --Real time quotes

May 17, 2022, 12:54 p.m.

/zigman2/quotes/203556943/composite

$

11.07

Change

+0.45 +4.24%

Volume

Volume 387,544

Real time quotes

/zigman2/quotes/203556943/composite

Previous close

$ 10.62

$ 11.07

Change

+0.45 +4.24%

Day low

Day high

$10.42

$11.13

Open

52 week low

52 week high

$6.51

$38.91

Open

Annual Financials for Deciphera Pharmaceuticals Inc.

Fiscal year is January-December. All values USD millions. 20172018201920202021 5-year trend
Sales/Revenue --25M42.09M96.15M
Cost of Goods Sold (COGS) incl. D&A 150,000317,000-5.36M9.39M
COGS excluding D&A ---225,0002.93M
Depreciation & Amortization Expense 150,000317,000830,0005.14M6.46M
Depreciation 150,000317,000830,0005.14M6.46M
Amortization of Intangibles -----
Gross Income (150,000)(317,000)-36.72M86.76M
20172018201920202021 5-year trend
SG&A Expense 50.79M103.78M224.9M307.91M360.63M
Research & Development 39.51M82.89M156.78M196.67M231.83M
Other SG&A 11.27M20.9M68.12M111.25M-
Other Operating Expense -----
Unusual Expense ----26.2M
EBIT after Unusual Expense ----(300.08M)
Non Operating Income/Expense 746,0004.33M8.54M4.7M113,000
Non-Operating Interest Income -----
Equity in Affiliates (Pretax) -----
Interest Expense 95,00084,00067,000--
Gross Interest Expense 95,00084,00067,000--
Interest Capitalized -----
Pretax Income (50.28M)(99.85M)(192.26M)(266.49M)(299.96M)
Income Tax -----
Income Tax - Current Domestic -----
Income Tax - Current Foreign -----
Income Tax - Deferred Domestic -----
Income Tax - Deferred Foreign -----
Income Tax Credits -----
Equity in Affiliates -----
Other After Tax Income (Expense) -----
Consolidated Net Income (50.28M)(99.85M)(192.26M)(266.49M)(299.96M)
Minority Interest Expense -----
Net Income (50.28M)(99.85M)(192.26M)(266.49M)(299.96M)
Extraordinaries & Discontinued Operations -----
Extra Items & Gain/Loss Sale Of Assets -----
Cumulative Effect - Accounting Chg -----
Discontinued Operations -----
Net Income After Extraordinaries (50.28M)(99.85M)(192.26M)(266.49M)(299.96M)
Preferred Dividends -----
Net Income Available to Common (50.28M)(99.85M)(192.26M)(266.49M)(299.96M)
EPS (Basic) (2.99)(2.82)(4.48)(4.78)(5.16)
Basic Shares Outstanding 16.79M35.39M42.87M55.78M58.08M
EPS (Diluted) (2.99)(2.82)(4.48)(4.78)(5.16)
Diluted Shares Outstanding 16.79M35.39M42.87M55.78M58.08M
EBITDA (50.79M)(103.78M)(199.9M)(266.05M)(267.42M)
Link to MarketWatch's Slice.